Sanofi has extended its master services agreement with Swedish drug discovery firm Beactica to characterise the interactions between new therapeutics and their target proteins.

The three-year extension agreement covers the legal terms associated with the collaboration, which has been ongoing since 2015.

Under the partnership, Beactica scientists have worked with Sanofi for the analysis of the kinetics that occurs when insulin analogues interact with their two binding sites present on the full-length insulin receptor.

Findings from this alliance are said to have contributed towards the regulatory approval of Sanofi’s rapid-acting insulin biosimilar called Insulin lispro Sanofi.

“We look forward to continuing our fruitful collaboration with Sanofi.”

Beactica CEO Dr Per Källblad said: “We are pleased to extend our agreement with Sanofi and look forward to continuing our fruitful collaboration.

“It is very rewarding to see tangible evidence on how Beactica’s expertise and capabilities contribute towards products that increase the quality of life for patients living with compromised health conditions.”

Founded in 2006, Beactica uses in-house methodologies to investigate molecule interactions for developing new therapeutics.

The firm also conducts drug discovery programmes to address areas with unmet medical need and allows collaborations for fragment-based lead generation using its discovery platform.

Beactica have established partnerships with numerous pharmaceutical and biotech companies, including Boehringer Ingelheim and Johnson & Johnson’s subsidiary Janssen R&D.